Valby, Denmark, January 20, 2020 — H. Lundbeck A/S’ (Lundbeck’s) continued efforts to reduce CO2-emissions and energy consumption are recognized as world leading by the independent interest group Carbon Disclosure Project (CDP), which sets the global standard for actions against climate change.
Lundbeck is included on the CDP’s new 2019 Climate A-list, the highest possible rating awarded to only the top 2% of the more than 8,400 companies surveyed by CDP worldwide.
The A-listing is a recognition of Lundbeck’s many different efforts to reduce its impact on the climate by reducing CO2-emissions and energy consumption. Since 2006, Lundbeck has reduced its CO2-emissions by 32,000 tons and its energy consumption by 51,000 MWh, the latter equaling the yearly power consumption of more than 11,000 households. The reductions correspond to 68% and 35% respectively.
“We are proud to receive this recognition of our ongoing efforts to reduce the climate impact of our business, even while the business has grown. It goes to show that significant results can be achieved through a long-term commitment to limit environmental impact,” says Deborah Dunsire, President and CEO of Lundbeck.
Lundbeck works with four overall categories of initiatives to reduce emissions and energy consumption: Optimization of existing buildings, plants and installations, investing in new low-energy machines and plants, shifts from conventional fuel to bio-fuel and general optimization reducing office spaces and buildings in use.
In addition to its own direct initiatives, Lundbeck seeks to participate in climate partnerships. To this end, Lundbeck joined the global movement “Business Ambition for 1.5°C” of companies aligning their business actions with the Paris Agreement. Further, Lundbeck is part of the Danish government’s Climate Panel for Life Science and Biotech to help provide industry-wide climate recommendations.
“Taking climate action is a shared responsibility, and we are dedicated to do our part. Not just by attending to our own business, but also by collaborating and hopefully helping other companies in their efforts to reduce environmental impact,” says Deborah Dunsire.
Mikkel Ballegaard Pedersen
Journalist, Corp. Communication
+45 30 83 20 44
Senior Director, Corp. Communication
+45 36 43 40 00
Lundbeck is a global biopharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health so every person can be their best.
An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.
Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and California and our production facilities are located in Denmark, France and Italy.
In the U.S., Lundbeck employs more than 900 people focused solely on accelerating therapies for brain diseases. With a special commitment to the lives of patients, families and care partners, Lundbeck U.S. actively engages in hundreds of initiatives each year that support our patient communities. For additional information, visit www.lundbeckus.com and connect on Twitter at @LundbeckUS.